Total Voting Rights and Capital

Haleon PLC
21 March 2024
 

Icon Description automatically generated

 

 

Haleon plc: Total Voting Rights and Capital

 

21 March 2024: Haleon plc ("Haleon" or the "Company) announces that the Company has today cancelled 102,272,727 ordinary shares of £0.01 each, repurchased from Pfizer Inc.

 

As at 21 March 2024 the total number of shares issued by Haleon plc with rights to vote is 9,132,301,104 ordinary shares of £0.01 each. There are no ordinary shares held in Treasury.

 

The figure of 9,132,301,104 may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The person responsible for arranging the release of this announcement on behalf of Haleon is Amanda Mellor, Company Secretary.

 

 

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Haleon (HLN)
UK 100

Latest directors dealings